Polypyridylruthenium(II) complexes exert in vitro and in vivo nematocidal activity and show significant inhibition of parasite acetylcholinesterases

Madhu Sundaraned1, Ramon M. Eichenbergerb, Rafid Al-Hallafb, Dai Yangb, Javier Sotillob, Siji Rajana, Phurpa Wangchukb, Paul R. Giacominc, F. Richard Keeneb,c, Alex Loukasc, J. Grant Collinsna,1, Mark S. Pearsonb,

a School of Physical, Environmental and Mathematical Sciences, UNSW (ADFA), Canberra, Australian Capital Territory, 2612, Australia
b Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, 4878, Australia
c School of Physical Sciences, University of Adelaide, Adelaide, South Australia, 5005, Australia

A R T I C L E  I N F O

Keywords:
Acetylcholinesterase
Trichuris muris
Ruthenium complex
Anthelmintic

A B S T R A C T

Over 4.5 billion people are at risk of infection with soil transmitted helminths and there are concerns about the development of resistance to the handful of frontline nematocides in endemic populations. We investigated the anti-nematode efficacy of a series of polypyridylruthenium(II) complexes and showed they were active against L3 and adult stages of Trichuris muris, the rodent homologue of the causative agent of human trichuriasis, T. trichiura. One of the compounds, Rubb12-mono, which was among the most potent in its ability to kill L3 (IC50 = 3.1 ± 0.4 μM) and adult (IC50 = 5.2 ± 0.3 μM) stage worms was assessed for efficacy in a mouse model of trichuriasis by administering 3 consecutive daily oral doses of the drug 3 weeks post infection with the murine whipworm Trichuris muris. Mice treated with Rubb12-mono showed an average 66% reduction (P = 0.015) in faecal egg count over two independent trials. The drugs partially exerted their activity through inhibition of acetylcholinesterases, as worms treated in vitro and in vivo showed significant decreases in the activity of this class of enzymes. Our data show that ruthenium complexes are effective against T. muris, a model gastro-intestinal nematode and soil-transmitted helminth. Further, knowledge of the target of ruthenium drugs can facilitate modification of current compounds to identify analogues which are even more effective and selective against Trichuris and other helminths of human and veterinary importance.

1. Introduction

More than 4.5 billion people worldwide are at risk of infection by soil-transmitted helminths (STHs) and over one-third of this number are infected with these parasites (Ascaris lumbricoides – 0.8 billion infections), whipworm (Trichuris trichiura - 0.46 billion) and hookworms (Necator americanus and Ancylostoma duodenale - 0.44 billion) (Pullan et al., 2014). STHs are prevalent in more than 100 countries (Gan et al., 2009), particularly in developing tropical and subtropical regions (Sub-Saharan Africa, East Asia and South America) where the hygiene conditions and sanitation practises are poor.

STH infections rarely cause death; rather, they cause chronic and insidious effects on the host’s health with clinical manifestations correlating with infection intensity. Heavy infection causes extensive morbidities such as intestinal disturbances, nutrition loss, physical and intellectual growth retardation and severe anaemia, particularly in pre- and school-aged children (Brooker et al., 1999; Stoltzfus et al., 2000). STH remains a serious problem in public health with a global burden of 4.98 million years lost to disability (YLDs) (Pullan et al., 2014), which approaches that caused by malaria.

Despite the public-health importance of these infections, these diseases have been neglected by the medical and international communities, predominantly because they are concentrated in very poor communities and the diseases can often be overshadowed by other public health or social issues. But, in recent years, the control of STH has become more important in public health management, and combat strategies have been proposed after the World Health Assembly resolution in 2001, with the administration of anthelmintics being the cornerstone of these programmes (Loukas and Bethony, 2008).

Five drugs (albendazole, mebendazole, pyrantel pamoate,
levamisole, and ivermectin) are currently available for the treatment of STH, yet control programmes rely heavily on only the two benzimidazoles (albendazole and mebendazole) because of economical and operational feasibility (Tritten et al., 2011).

There is no direct evidence for emerging resistance to any of the current anthelmintics in human helminth populations, however, low cure rates have been reported for *T. trichiura* and hookworm infections (Keiser and Utzinger, 2010). Repeated and prolonged administration of these anthelmintics, necessitated by sub-optimal drug efficacy, increases the risk of resistance developing and has already been well documented among nematodes of veterinary importance, and is increasing in frequency as a consequence of extensive use of benzimidazoles over extended periods of time (Kaplan, 2004).

Among potential targets for nematode chemotherapy are acetylcholinesterases (AChEs). These enzymes catalyse the rapid breakdown of the neurotransmitter acetylcholine (ACh) in both central and peripheral nervous systems of eukaryotic organisms, and so control neuronal function (Massoulie et al., 1993). In addition to controlling cholinergic synapses, multiple isoforms of the enzyme are secreted from many nematodes in large amounts and have been implicated in mediating pathogenesis of nematode infection by modulating the host immune system through the disruption of host cholinergic signalling (Selkirk et al., 2005; Vaux et al., 2016) and providing acetate and choline precursors for helminth metabolism (Lee, 1996).

With respect to its termination of synaptic transmission, inhibition of AChE produces an excess accumulation of ACh and overstimulation of its receptors, causing uncoordinated neuromuscular function that often results in death due to respiratory paralysis (Thapa et al., 2017). As such, AChE inhibitors are widely used as pesticides (Kwong, 2002) and anthelmintics (Orhan, 2013). Indeed, metrifonate, an organophosphorus AChE inhibitor originally used as an insecticide, has also been used for the treatment of human and veterinary nematode infections (Thompson et al., 1996) but now has limited use as a therapeutic because of off-target toxicity (Kramer et al., 2014). Moreover, the frontline nematocides all target the neuromusculature of these parasites (Thompson et al., 1996) although they are not necessarily inhibitors of AChE.

In addition to organophosphates, mono-nuclear chemical complexes of the transition metal ruthenium have been shown to target and inhibit enzymes such as AChE (Vyas et al., 2014), and there are numerous recent studies documenting the efficacy of polypyridylruthenium(II) complexes against a variety of different microbial pathogens (Li et al., 2011; Pandrala et al., 2013; Gorle et al., 2014). Unlike their organophosphorus counterparts, ruthenium complexes are speculated to exert their inhibitory effects through a combination of electrostatic and hydrophobic interactions at the peripheral anionic (PAS) site of AChE, which is located at the gate of the enzyme’s catalytic gorge (Bourne et al., 2005), and not through direct interaction with the active site. Ruthenium complexes are thought to be less toxic to human cells than small-molecule inhibitors because of this mode of inhibition and also because the overall neutral charge in the outer membrane leaflet of eukaryotic cells (Mason et al., 2007) creates a greatly reduced capacity for electrostatic interaction with the metal compounds (Gorle et al., 2016).

Herein, we demonstrate the AChE-inhibitory action of two mono-nuclear and a series of di-, tri- and tetra-nuclear polypyridylruthenium (II) (ruthenium) complexes linked by the bis(4′-methyl-2,2′-bipyridyl)-1,n-alkane ligand (\(\text{bb}n\); \(n = 7, 10, 12\) and 16) against extracts of *T. muris* and *Ancylostoma caninum* (helminths used as models of human trichuriasis and hookworm infection, respectively) and both adult and L3 stage *T. muris* parasites in *vitro*. We also show the *in vivo* efficacy of one of these ruthenium complexes (Rubb12-mono) in a mouse model of trichuriasis, providing evidence that drugs based on these compounds could be a valuable addition to the chemotherapeutic arsenal against both human and veterinary nematode infections.

2. Materials and methods

2.1. Nomenclature and preparation of ruthenium complexes

\([\text{Ru(phen)}_2(\text{Me}_2\text{bpy})]^{2+}\) (phen = 1,10-phenanthroline; Me₂bpy = 4′,4′-dimethyl-2,2′-bipyrindine) and the mononuclear (Rubb₁-mono), dinuclear (Rubb₂-di), trinuclear (Rubb₃-tri), tetranclear linear (Rubb₄-tl) and tetranclear non-linear (Rubb₄-tnl) polypyridylruthenium(II) complexes (Fig. 1) were synthesised using the appropriate bis(4′-(4-methyl-2,2′-bipyridyl)-1,n-alkane ligand (bbₙ) as.
previously described (Gorle et al., 2014). All ruthenium complexes were chloride salts and were dissolved in H2O at stock concentrations of 1 mM.

2.2. Animals and parasites

Six-to-eight-week old male B10.BR mice were purchased from the Animal Resource Centre, Canningvale, Western Australia and allowed to acclimatise for one week before infection. Mice were orally infected with 200 μl of PBS containing approximately 200 live embryonated T. muris eggs. All animals were kept in groups of 5 mice in cages with free access to water and food and with a 12-h light/dark cycle. Third stage larvae (L3) and adult worms were harvested from the caecum by sacrificing the mice after three weeks and five weeks, respectively. Both stages were washed with PBS containing 2 × antibiotic/antimycotic (AA) and used for either extract preparation (adult) or in vitro experiments (adult and L3).

2.3. Parasite extract preparation

Freshly harvested adult T. muris or A. caninum (thawed from -80 °C stocks) were homogenised (10 parasites/200 μl) in PBS containing 1% Triton X-100, 40 mM Tris-HCl, pH 7.4, at 4 °C using a TissueLyser II (Qiagen) and the supernatant collected by centrifugation at 15,000 × g for 60 min at 4 °C. Protein concentration was determined using the Pierce Protein Assay kit (Thermo sher) and immediately assayed for AChE activity. Each assay was technically replicated three times. For each enzyme assay, activities of drug-treated parasites were expressed relative to worms cultured without ruthenium complexes (negative controls). Data is the average of assays run on triplicate extracts and three technical replicates of each assay ± SE.

2.4. Enzyme activity in parasite extracts and inhibition assays

AChE activity in Triton X-100-soluble adult T. muris and A. caninum extracts was determined in a Polarstar Omega microplate reader (200 μl final volume in 96-well plates) using the Ellman method (Ellman et al., 1961). Extracts were serially diluted (40-10 μg) in AChE assay buffer (0.1 M sodium phosphate, pH 7.4), 2 μM acetyl-thiocholine (AcSCh) and 0.5 mM 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) were added and absorbance was measured (405 nm) every 10 min for 5 h at 37 °C. Specific activity was calculated using the initial velocity of the reaction. For AChE inhibition assays, extract equal to a specific activity of 0.55 nmol/min/well (T. muris - 30 μg, A. caninum – 20 μg) were diluted in AChE assay buffer to a final volume of 170 μl and pre-incubated with ruthenium complexes (10 nM–100 μM) for 20 min at RT. AcSCh and DTNB were added at 2 μM and 0.5 mM, respectively and absorbance was measured (405 nm) every 10 min for 5 h at 37 °C. Inhibition for each sample was calculated relative to the negative control (reactions without ruthenium complexes) and reactions were performed in duplicate.

2.5. In vitro activity of ruthenium complexes against adult and L3 stage T. muris

Ruthenium complexes were dissolved in sterile PBS for use in the assay. Adult or L3 stage worms were transferred in groups of 4 into each well of a 48-well plate containing 0.5 ml pre-warmed RPMI medium supplemented with 2 × AA and cultured with ruthenium complexes (50 μM). Control worms were treated with the PBS vehicle. All worms were incubated at 37 °C and 5% CO2 for 72 h and monitored every 24 h for motility by microscopic examination (20 × ). The viability of the worms was evaluated according to previously reported protocols (Tritten et al., 2012; Keiser et al., 2013) using a motility score from 0 to 3 (0 = dead, 1 = very low motility, 2 = low motility, 3 = normal motility). IC50 values of the two most effective ruthenium complexes were then similarly tested at different concentrations ranging from 3.125 to 50 μM. Assays were conducted in duplicate and data is represented as the average of these two experiments ± SE. Albendazole was used at 200 μg/ml - the IC50 previously determined against adult and L3 stage T. muris (Tritten et al., 2011) - as a positive control in all experiments.

2.6. Enzyme inhibition studies on ruthenium complex-treated adult T. muris

Groups of five, freshly isolated adult T. muris were cultured in the presence of sub-lethal concentrations of either Rubb12-mono and Rubb12-tri (6.25 μM in PBS) or PBS alone in RPMI medium supplemented with 2 × AA. Three sets of five worms were used for each drug tested. Worms were collected after 24 h when they were still motile. Triton X-100-soluble extracts were made from each set of five worms (so, three extracts for each drug tested), quantified using the Pierce BCA Protein Assay kit (Thermofisher) and immediately assayed for AChE activity. Each assay was technically replicated three times. For each enzyme assay, activities of drug-treated parasites were expressed relative to worms cultured without ruthenium complexes (negative controls). Data is the average of assays run on triplicate extracts and three technical replicates of each assay ± SE.

2.7. Tolerability study

In order to determine the appropriate dose of Rubb12-mono to be used in the in vivo study, the maximum tolerated dose was determined for the B10.BR mouse strain. Rubb12-mono was administered to groups of three male mice for three consecutive days. The doses ranged from 5 to 20 mg/kg. Animals were closely monitored for adverse clinical signs throughout the study and mice showing adverse effects were euthanised using CO2 asphyxiation. The highest dose that did not cause any adverse clinical signs for three consecutive daily doses was considered to be the maximum tolerated dose (MTD).

2.8. In vivo efficacy of Rubb12-mono

The in vivo efficacy of Rubb12-mono was tested in two independent trials. For each trial, groups of nine male B10.BR mice (6-8 weeks old) were each orally infected with 200 μl of PBS containing approximately 200 live embryonated T. muris eggs. At 28 days p.i., one group was given three consecutive daily oral doses (200 μl) of Rubb12-mono (2 × 10 mg/kg in PBS and 1 × 5 mg/kg in PBS) and the other (negative control group) was given three consecutive daily oral doses (200 μl) of PBS. Mice were sacrificed at 35 days p.i. and worms were harvested from the caecum and counted manually using light microscopy (20 × magnification). The worm burden reduction (WBR) was calculated as: \[ \frac{\text{average worm count in the treated group}}{\text{average worm count in the negative control group}} \times 100\% \], where a = average worm count in the negative control group and b = average worm count in a treated group. Faecal samples (approximately 0.1 g) from each individual mouse were collected 24 h before necropsy, homogenised in 2 ml of saturated NaCl overnight at 4 °C and the number of eggs counted in triplicate using a Whittlock McMaster counting chamber. This number was used to determine the number of eggs per gram (EPG) of faeces and reduction calculated as for WBR. Extracts were prepared from equal numbers of worms harvested from each individual mouse of each group (trial 1 control – n = 9 mice, trial 1 treatment – n = 6 mice, trial 2 control – n = 9 mice, trial 2 treatment – n = 7 mice) and assayed in triplicate for AChE activity. For each trial, differences in AChE activity was calculated by comparing the average of all extracts from the treatment group with the average (± SE) of all extracts from the control group.

2.9. Statistical analyses

Statistical analyses were performed using Graphpad Prism 7. Inhibition curves and IC50 values were generated using sigmoidal dose-response (variable slope) with a non-linear fit model. One-way ANOVA with Dunn’s multiple comparison was used to determine significance (p), which was set at 0.05. In the case where only two groups were compared (in vivo studies), student’s t-test with Welch’s correction was
Table 1
Inhibition and the potency (IC50) of the series of ruthenium complexes against AChE activity in adult T. muris extracts. Ruthenium complexes that showed the highest potency are highlighted (bold).

<table>
<thead>
<tr>
<th>Compound</th>
<th>AChE inhibition (%)</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Ru(phen)2(Me2bpy)]2+</td>
<td>0.7 ± 0.6</td>
<td>31.26 ± 1.17</td>
</tr>
<tr>
<td>Rubb-tri</td>
<td>81.6 ± 0.3</td>
<td>0.29 ± 0.00</td>
</tr>
<tr>
<td>Rubb-5l</td>
<td>76.9 ± 0.5</td>
<td>0.52 ± 0.02</td>
</tr>
<tr>
<td>Rubb-lnl</td>
<td>93.2 ± 0.5</td>
<td>0.12 ± 0.02</td>
</tr>
<tr>
<td>Rubb12-tri</td>
<td>86.8 ± 0.7</td>
<td>0.06 ± 0.00</td>
</tr>
<tr>
<td>Rubb12-mono</td>
<td>5.0 ± 0.3</td>
<td>2.30 ± 0.25</td>
</tr>
<tr>
<td>Rubb12-di</td>
<td>68.7 ± 0.9</td>
<td>0.35 ± 0.08</td>
</tr>
<tr>
<td>Rubb12-tri</td>
<td>65.4 ± 0.2</td>
<td>1.00 ± 0.05</td>
</tr>
<tr>
<td>Rubb12-tl</td>
<td>81.2 ± 0.1</td>
<td>0.83 ± 0.06</td>
</tr>
<tr>
<td>Rubb12-tl</td>
<td>90.7 ± 0.8</td>
<td>0.24 ± 0.01</td>
</tr>
<tr>
<td>Rubb12-tri</td>
<td>76.4 ± 0.7</td>
<td>0.47 ± 0.04</td>
</tr>
<tr>
<td>Rubb12-tl</td>
<td>69.5 ± 0.7</td>
<td>0.47 ± 0.04</td>
</tr>
<tr>
<td>Rubb12-lnl</td>
<td>91.9 ± 0.0</td>
<td>0.25 ± 0.00</td>
</tr>
</tbody>
</table>

a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.

Table 2
Inhibition and the potency (IC50) of the series of ruthenium complexes against AChE activity in adult A. caninum extracts. Ruthenium complexes that showed the highest potency are highlighted (bold).

<table>
<thead>
<tr>
<th>Compound</th>
<th>AChE inhibition (%)</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Ru(phen)2(Me2bpy)]2+</td>
<td>56.8 ± 0.0</td>
<td>0.6 ± 0.0</td>
</tr>
<tr>
<td>Rubb-tri</td>
<td>71.4 ± 1.0</td>
<td>ND</td>
</tr>
<tr>
<td>Rubb-tl</td>
<td>76.6 ± 0.1</td>
<td>0.2 ± 0.0</td>
</tr>
<tr>
<td>Rubb-lnl</td>
<td>47.1 ± 0.5</td>
<td>0.8 ± 0.0</td>
</tr>
<tr>
<td>Rubb12-tri</td>
<td>58.5 ± 0.1</td>
<td>1.0 ± 0.0</td>
</tr>
<tr>
<td>Rubb12-mono</td>
<td>18.4 ± 3.4</td>
<td>18.1 ± 0.2</td>
</tr>
<tr>
<td>Rubb7-dil</td>
<td>57.1 ± 1.0</td>
<td>0.8 ± 0.0</td>
</tr>
<tr>
<td>Rubb7-tri</td>
<td>55.4 ± 0.4</td>
<td>0.9 ± 0.0</td>
</tr>
<tr>
<td>Rubb7-tl</td>
<td>59.7 ± 0.2</td>
<td>0.6 ± 0.0</td>
</tr>
<tr>
<td>Rubb7-tlnl</td>
<td>39.4 ± 0.7</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td>Rubb12-tri</td>
<td>43.6 ± 0.2</td>
<td>ND</td>
</tr>
<tr>
<td>Rubb12-tl</td>
<td>37.0 ± 1.0</td>
<td>1.0 ± 0.1</td>
</tr>
<tr>
<td>Rubb12-lnl</td>
<td>27.6 ± 2.1</td>
<td>3.5 ± 0.3</td>
</tr>
</tbody>
</table>

a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.

3. Results

3.1. Inhibition of AChE activity in adult T. muris extracts

A series of ruthenium complexes were screened at 1 μM for AChE inhibitory activity in T. muris adult parasite extract. Except for [Ru(phen)2(Me2bpy)]2+ and Rubb12-mono, all complexes inhibited 65-93% AChE activity (Table 1). The IC50 for each ruthenium complex against AChE activity was also determined. Except for [Ru(phen)2(Me2bpy)]2+, all complexes exhibited IC50 values between sub-to low-micromolar concentrations with Rubb10-tri and Rubb-tlnl being the most potent, having IC50 values of 61 and 120 nM, respectively (Table 1).

3.2. Inhibition of AChE activity in adult A. caninum extracts

Since the ruthenium complexes inhibited AChE activity in T. muris extract, we explored the inhibitory activities of the compounds in extracts of A. caninum (Table 2). The series displayed a more varied range of activity than was seen for T. muris, with AChE inhibition ranging from 18 to 76%. Rubb7-tl and Rubb12-tl showed the greatest inhibitory activity against A. caninum extracts, with IC50 values of 0.2 ± 0.01 μM and 0.6 ± 0.03 μM, respectively. AChE inhibition increased with increasing nuclearity of the ruthenium centres only to the level of the dinuclear complex, with the inhibition by Rubb12-mono < Rubb12-di in Rubb12-tri = Rubb12-tl (Table 2) (Fig. 2).

3.3. In vitro effect of ruthenium complexes against L3 and adult T. muris

Four L3 T. muris larvae were cultured in the presence of each ruthenium complex (50 μM) and the parasite motility was monitored at 24 and 48 h (Fig. 3). Treatment with Rubb12-mono and Rubb12-tri complexes resulted in 100% worm death in 24 h, whereas most of the
3.5. Tolerability of Rubb12-mono

M. Sundaraneedi et al.
IJP: Drugs and Drug Resistance 8 (2018) 1–7
displayed IC50 values of 3.1 ± 0.4 and 2.3 ± 0.3 were tested at different concentrations against L3 stage worms and displayed IC50 values of 3.1 ± 0.4 and 2.3 ± 0.3 μM, respectively (Table 3). In identical experiments with adult parasites, Rubb12-mono and Rubb12-tri were the most effective, killing 100% of adult worms in 24 h (Fig. 4). IC50 values were subsequently determined as 3.1 ± 0.4 and 2.3 ± 0.3 μM, respectively (Table 3).

3.6. In vivo efficacy of Rubb12-mono against T. muris

Based on the significant in vitro activity against T. muris adults and L3 stage worms, Rubb12-mono was further assessed for its in vivo efficacy using a mouse model of T. muris infection. Three weeks after infection, Rubb12-mono was orally administrated once daily for 2 days at 10 mg/kg with a 5 mg/kg dose administered on the third day. Worm and faecal egg counts were assessed at 5 weeks p.i. (Fig. 6). For trial 1, Rubb12-mono-treated mice achieved significant reductions in worm (35%, \( P = 0.0396 \)) and egg (82%, \( P = 0.0034 \)) counts, compared to PBS treated controls. Further, extracts made from worms recovered from treated mice showed significantly less AChE activity (\( P = 0.0044 \)) than extracts from worms recovered from control animals. There was a non-significant decrease (11%, \( P = 0.279 \)) in the worm burden of Rubb12-mono-treated mice in trial 2 compared to controls and no difference in the AChE activity of extracts made from worms recovered from treated and control mice. However, the faecal egg count seen in treated mice was significantly lower (50%, \( P = 0.0155 \)) than control animals from this trial. Over the two independent trials, the average reduction in faecal egg count was 66% (\( P = 0.015 \)), compared to controls.

4. Discussion

Over 1.5 billion people are infected with soil-transmitted helminths (STHs), no anti-STH vaccines are available and there is evidence that resistance to the handful of drugs used to control this scourge is developing. In this study, we have investigated the activity of a series of ruthenium complexes against two model species of STHs - T. muris and A. caninum - have shown that these compounds are capable of inhibiting AChE activity in extracts made from the parasites and, at least for T. muris, the nematocidal action of ruthenium complexes could be partially due to AChE inhibition, an enzyme vital to the neuromuscular function of these helminths.

With regard to the AChE-inhibitory properties of ruthenium complexes against parasite extracts, no specific relationship between compound structure and activity was observed with T. muris extracts, although all the ruthenium complexes inhibited AChE activity at submicromolar to micromolar concentrations with specific tri- and tetra-nuclear complexes displaying the most potent activity. Conversely, a structure/activity relationship was observed for tetra-nuclear ruthenium complex inhibition of A. caninum extracts, with potency increasing with decreasing chain length between the ruthenium centres. The mononuclear ruthenium complexes are thought to interact with the

Table 3
Potency of Rubb12-mono and Rubb12-tri against L3 and adult stages of T. muris.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC50 (μM)(^{a,b})</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L3</td>
</tr>
<tr>
<td>Rubb12-mono</td>
<td>3.1 ± 0.4</td>
</tr>
<tr>
<td>Rubb12-tri</td>
<td>2.3 ± 0.3</td>
</tr>
</tbody>
</table>

\(^a\) Data represent the mean of duplicate experiments ± SE.

\(^b\) Values determined after 24 h (L3) and 48 h (adult) incubation with compounds.
PAS of AChE located at the rim of the active-centre gorge through a combination of electrostatic and hydrophobic interactions (Meggers, 2009). The tri- and tetra-nuclear complexes showed greater activity compared to mononuclear complexes, presumably due to the presence of the flexibly-linked multiple metal centres which may provide more interactions (electrostatic and hydrophobic) with the PAS, or each individual centre may contribute nonspecific additional points of contact. That the activity of the ruthenium complexes varied between T. muris and *A. caninum* extracts is likely due to differences in enzyme orthologues and the existence of multiple isoforms of AChE which are present in different helminth species (Arnon et al., 1999; Selkirk et al., 2005).

Encouraged by the activity of ruthenium complexes in *T. muris* adult parasite extracts, their effect against the L3 and adult stages in vitro were examined. With minor differences in sensitivity, Rubb12-mono and Rubb12-tri showed excellent activity against both stages of the parasite with both complexes exhibiting dose-dependent lethal effects. However, the results of motility experiments did not correlate with inhibition of enzyme activity in worm extracts, especially with Rubb12-mono, which was one of the most effective compounds against both L3 and adult parasites, but not with regards to inhibiting AChE activity in extracts. This is possibly due to the differential accessibility of inhibitor to enzyme in an extract preparation compared to a living parasite. Another explanation is that the mechanism of action of ruthenium complexes is multi-faceted and not just confined to AChE inhibition in extracts. This is supported by the variation in enzyme ortho-functional correlates between bacteria and eukaryotic cells. J. Antimicrob. Chemother. 71, 246–246.

PAS of AChE located at the rim of the active-centre gorge through a combination of electrostatic and hydrophobic interactions (Meggers, 2009). The tri- and tetra-nuclear complexes showed greater activity compared to mononuclear complexes, presumably due to the presence of the flexibly-linked multiple metal centres which may provide more interactions (electrostatic and hydrophobic) with the PAS, or each individual centre may contribute nonspecific additional points of contact. That the activity of the ruthenium complexes varied between *T. muris* and *A. caninum* extracts is likely due to differences in enzyme orthologues and the existence of multiple isoforms of AChE which are present in different helminth species (Arnon et al., 1999; Selkirk et al., 2005).

Encouraged by the activity of ruthenium complexes in *T. muris* adult parasite extracts, their effect against the L3 and adult stages in vitro were examined. With minor differences in sensitivity, Rubb12-mono and Rubb12-tri showed excellent activity against both stages of the parasite with both complexes exhibiting dose-dependent lethal effects. However, the results of motility experiments did not correlate with inhibition of enzyme activity in worm extracts, especially with Rubb12-mono, which was one of the most effective compounds against both L3 and adult parasites, but not with regards to inhibiting AChE activity in extracts. This is possibly due to the differential accessibility of inhibitor to enzyme in an extract preparation compared to a living parasite. Another explanation is that the mechanism of action of ruthenium complexes is multi-faceted and not just confined to AChE inhibition in extracts. This is supported by the variation in enzyme ortho-functional correlates between bacteria and eukaryotic cells. J. Antimicrob. Chemother. 71, 246–246.

Rubb12-mono was one of the most effective compounds with regards to in vitro anti-*Trichuris* activity and was therefore tested for efficacy in a mouse model of *Trichuris* infection. Surprisingly, Rubb12-mono was found to be more toxic by oral administration than what has been reported for simple polypyridylruthenium complexes (eg: [Ru(phen) 3]2+) (Brandt et al., 1994). This is probably due to a higher rate of absorption of Rubb12-mono from the intestine into the blood. The complex showed promising in vivo activity at tolerated doses in mice, with treatment resulting in reductions in worm (only significant in trial 1) and egg counts (significant in both trials), compared to controls. Rubb12-mono-treated mice in trial 2 had a significantly higher worm load than those in trial 1 and this may explain the reduced efficacy of Rubb12-mono in the repeat trial. Regardless of the variation in parasite load, reduction in egg count was not only significant in both trials but also more pronounced than worm decrease, implying that egg count reduction was not just concomitant with worm burden reduction and that Rubb12-mono treatment affected parasite maturation and fecundity. Further, parasites recovered from Rubb12-mono-treated mice showed significantly decreased AChE activity than those harvested from control mice (consistent with in vitro results), suggesting that nematocidal activity was a result of drug-induced inhibition of enzyme activity. Since reductions in both worm and egg counts are required for efficacy of anthelmintics, the in vivo results suggest the potential of Rubb12-mono as a drug lead for the development of novel nematocides to reduce infection pathology and interrupt disease transmission. Further, due to the uniquely shared neurobiology of helminths compared with higher eukaryotes (Thompson et al., 1996), we believe ruthenium complexes could exert broad spectrum anthelmintic activity while being relatively non-toxic and, due to the modular nature of these compounds, these drugs could be tailored to target specific regions of molecules, further enhancing their activity and selectivity.

**References**


**Fig. 6**. Treatment of *T. muris*-infected mice with Rubb12-mono. Decrease in trial 1 worm burden (A) was determined by comparing parasite burdens from treated and control mice. (B) AChE activity in Triton X-100 extracts made from worms recovered from control and treated mice. Extracts were made from equal amounts of worms collected from all surviving mice (control group – n = 9, treatment group – n = 6) and 30 μg of each extract was used to determine enzyme activity (performed in duplicate). Data is the mean of enzyme activity calculated from each individual extract for each group ± SE. Decrease in faecal egg count for (C) trial 1 and (D) trial 2 was determined by comparing faecal egg counts of control and treated mice. Symbols represent the average of triplicate counts from faeces obtained from individual mice. Differences were measured by unpaired t-test with Welch’s correction. *P* ≤ 0.05, **P** ≤ 0.01. In trial 2, the decrease in adult worm burden and reduction in enzyme activity from parasites recovered was not significant.